Bris­tol My­ers Squibb turns in pri­or­i­ty re­view vouch­er for sup­ple­men­tal in­di­ca­tion on an old Cel­gene drug

Af­ter turn­ing around Cel­gene’s S1P mod­u­la­tor for a long-await­ed ap­proval in mul­ti­ple scle­ro­sis, Bris­tol My­ers Squibb is now trad­ing in an FDA wild­card to get a quick re­view in ul­cer­a­tive col­i­tis.

BMS has re­deemed a pri­or­i­ty re­view vouch­er for a speedy de­ci­sion on its sup­ple­men­tal NDA for Zeposia, which hit the mar­ket this past June for MS. The FDA set a PDU­FA date for May 30 — and if giv­en the thumbs up, BMS says it would have the first oral sphin­go­sine-1-phos­phate (S1P) re­cep­tor mod­u­la­tor for UC.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.